Dabrafenib

Dabrafenib has been studied in 3 papers since 2026: none in people yet, 2 in animals, 1 in cells; 3 in the past year. The research so far is in animals and cells. The newest story, Oct 29, 2026: “Drug combination limited brain tumor regrowth in mice”.

Intervention

3 papers study it1 more mentions it1 findingUpdated Oct 29, 2026

PubChem ChEBI

1 new paper in 30 daysSee all 3

1 lab in 1 country
36 trials, none about aging, 5 with no results posted

Funders: Brain Tumour Charity and 6 more
19 of 36 trials sponsored by its developers

Animals2

What did studies of Dabrafenib find?

Studies of Dabrafenib measured 1 outcome; the most studied are cellular senescence (1 study).

Cellular senescence

upin human cells1

1 study

Dabrafenib induces cellular senescence in human cells (BT-40 cells treated in vitro).
“Senescence is induced in BT-40 cells in vitro when treated not only with Trametinib, but also with Dabrafenib and Vinblastine.”
CellsBT-40 cells treated in vitro
Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibition
bioRxiv (Cold Spring Harbor Laboratory)Jan 14, 2026Preprint

Who is developing Dabrafenib?

1 company: Novartis Pharmaceuticals.

Companies: Novartis PharmaceuticalsPhase 4melanoma, non-small cell lung cancer

Trial sponsors

Novartis Pharmaceuticals Corporation
Company17 trialsPhase 44,738 people
GSK
Company5 trialsPhase 2110 people
Immuneering Corporation
Company1 trialPhase 1/2209 people
Merck & Co.
Company1 trialPhase 1/2184 people
MedImmune
Company1 trialPhase 168 people
Kartos Therapeutics
Company1 trialPhase 131 people
National Cancer Institute
3 trialsPhase 3563 people
University of California, San Francisco
1 trialPhase 296 people

Latest

2 papers in 12 months

Neuro-oncologyOct 29

Drug combination limited brain tumor regrowth in mice

In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.

Mouse studyInterventions